Journal of Bacteriology, August 1999, p. 5131-5133, Vol. 181, No. 16
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Purification and Ligand Binding of EmrR, a
Regulator of a Multidrug Transporter
Alexei
Brooun,
John J.
Tomashek, and
Kim
Lewis*
Biotechnology Center, Tufts University,
Medford, Massachusetts 02155
Received 10 May 1999/Accepted 8 June 1999
 |
ABSTRACT |
EmrR, the repressor of the emrRAB operon of
Escherichia coli, was purified to 95% homogeneity. EmrR
was found to bind putative ligands of the EmrAB
pump
2,4-dinitrophenol, carbonyl cyanide m-chlorophenylhydrazone, and carbonyl cyanide
p-(trifluoro-methoxy)phenylhydrazone
with affinities in
the micromolar range. Equilibrium dialysis experiments suggested one
bound ligand per monomer of the dimeric EmrR.
 |
TEXT |
Bacteria have evolved mechanisms for
the neutralization or extrusion of toxic compounds from the cell
(6). Multidrug resistance pumps are integral membrane
proteins that transport a broad range of structurally diverse compounds
from the cell by using energy from either the proton motive force or
ATP (7, 17, 18).
In three cases described so far, expression of a multidrug pump is
increased by its chemically unrelated substrates via a transcriptional
regulator (reviewed in reference 8). In
Bacillus subtilis, BmrR, a MerR family transcriptional
activator, binds chemically unrelated hydrophobic cations, such as
tetraphenylphosphonium and rhodamine, and activates transcription of
the BMR pump (1). The structure of the C-terminal ligand
binding domain (13) of BmrR was recently resolved
(20). The design of the binding site agrees well with its
ability to accommodate a broad range of hydrophobic cations. In
Staphylococcus aureus, QacR, belonging to the TetR family of
repressors, also binds various hydrophobic cations and controls the
expression of the QacA MDR pump (5).
In Escherichia coli, transcription of the EmrAB pump is
controlled by EmrR, a 20.6-kDa protein that is encoded by the first gene of the emrRAB operon (11) and belongs to the
MarR family of transcriptional repressors (16, 19). EmrA and
EmrB form a multidrug pump that traverses the cell envelope and
extrudes the antibiotic thiolactomycin, uncouplers of the proton motive force, and possibly other hydrophobic compounds (4, 10). Repression of the emrRAB operon by EmrR is relieved in the
presence of inducers such as uncouplers of oxidative phosphorylation,
salicylic acid, 2,4-dinitrophenol (DNP), carbonyl cyanide
m-chlorophenylhydrazone (CCCP), and carbonyl cyanide
p-(trifluoro-methoxy)phenylhydrazone (FCCP) (11).
In addition to controlling the emr operon, EmrR (formerly
MprA) regulates expression of the mcb operon coding for
microcin B17 production (3, 9, 12).
The structural information gained from MDR regulators will be very
useful in understanding the general principles of multidrug recognition
that might be common to soluble multidrug sensors and the larger
multidrug pumps they regulate. Toward this aim, we have undertaken the
present study of ligand binding with purified EmrR.
Expression and purification of EmrR.
The emrR
coding sequence was cloned into pET-14b vector (Novagen, Madison, Wis.)
forming an N-terminal fusion with a histidine tag. EmrR was expressed
and purified by immobilized metal affinity chromatography (IMAC) to
95% homogeneity. After the His tag was cleaved with thrombin, the
purified protein migrated as a single band on sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with an apparent
molecular mass of 20 kDa (Fig. 1), in
good agreement with the calculated molecular mass of 20.6 kDa. A band
corresponding to a possible EmrR dimer was observed under nonreducing
conditions. Western blotting confirmed that the purified protein is
EmrR (data not shown). Gel filtration of the IMAC-purified EmrR
indicated the presence of two fractions with apparent molecular masses
of 54 kDa (calculated molecular mass of EmrR dimer is 41.5 kDa) and 89 kDa, respectively (data not shown). EmrR contains four cysteine
residues that may form intermolecular disulfide bonds and contribute to
formation of high-molecular-weight aggregates. The
high-molecular-weight species was not observed when gel filtration analysis was conducted in the presence of 100 mM dithiothreitol, suggesting that the putative tetramer was formed by disulfide cross-linking (EmrR has four cysteines). Reducing conditions did not
affect the dimer, suggesting that it is not held together by disulfide
bonds. The cytoplasm is strongly reduced, which suggests that the dimer
is the natural form of EmrR.

View larger version (108K):
[in this window]
[in a new window]
|
FIG. 1.
Affinity purification of EmrR. Protein was purified as
described above. Samples were loaded onto a 12.5% acrylamide SDS-PAGE
gel, run at 200 V until the dye front was at the bottom of the gel, and
then stained with Coomassie brilliant blue R-250. Lanes 1 and 7, molecular mass markers; lane 2, crude lysate; lane 3, material passed
through the IMAC column; lane 4, wash with 50 mM imidazole in binding
buffer; lane 5, elution with 200 mM imidazole in binding buffer; lane
6, EmrR after cleavage with thrombin.
|
|
Ligand binding properties of EmrR.
We examined three putative
ligands of EmrR
DNP, CCCP, and FCCP
all of which are easily assayed
spectrophotometrically. The substances absorb in the broad range of 260 to 400 nm, and absorbance at 380 nm was used to prevent interference
from protein absorbance. To determine whether these ligands bind
specifically to EmrR, crude extracts were prepared from cultures that
had been either induced (+EmrR) or not (
EmrR) with
isopropyl-
-D-thiogalactopyranoside (IPTG). EmrR without
a histidine tag was expressed for those experiments by using a pET-21a
vector (Novagen). Slide-a-Lyzer cassettes (Pierce) were loaded with 400 µl of 1-mg/ml extract and dialyzed ~16 h against 400 ml of a buffer
(50 mM Tris, 150 mM NaCl, 1 mM EDTA, 5% glycerol [pH 7.4])
containing various concentrations of ligand. Absorbance of protein was
determined from dialysis against buffer without ligand and subtracted
from all samples. Concentrations of ligand in both the bath and the
cassette were measured by calculating from a standard curve for each
ligand. To ensure that binding to protein had no effect on absorbance
by the ligand, samples were measured both before and after treatment
with proteinase K (data not shown). Bound ligand was determined by
subtracting the measured concentration of a given bath from the
concentrations measured from cassettes in that bath. Data were then
plotted according to Scatchard (Fig. 2).
The KS and the n[E]t
were calculated according to the following formula: [bound
ligand]/[free ligand] =
(n[E]t/KS)
([bound
ligand]/KS). CCCP showed specific binding, but
nonspecific binding was considerable, with a
KNS-CCCP of 4.8 µM relative to a
KS-CCCP of 1.3 µM, a 3.5-fold difference. FCCP
showed a higher degree of specificity
(KNS-FCCP = 62.5 µM versus
KS-FCCP = 1.3 µM, nearly a 50-fold
difference). DNP had no detectable nonspecific binding (the points
clustered around the origin of the plot) and a
KS-DNP of 11.1 µM in the crude extract (Fig.
2).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 2.
Equilibrium dialysis of EmrR bound to ligands. Ligand
concentrations were obtained by measuring absorbance at 380 nm with a
microtiter plate reader and referencing a corresponding calibration
curve that produced a linear absorbance/concentration relationship in
the 1 to 100 µM concentration range for each ligand. The data from
equilibrium dialysis measurements were plotted to determine the
KS (squares), KNS
(diamonds), and n[E]t (x axis
intercepts) for CCCP (A), FCCP (B), and DNP (C). The nonspecific data
for DNP clustered around the origin and are not shown. Each data point
is an average of three independent determinations. B, bound; F, free
ligand.
|
|
Once ligand binding to EmrR was determined to be specific, additional
ligand binding experiments were conducted with the IMAC-purified protein (Table 1). The concentration of
binding sites (n[E]t, i.e., n, the
number of binding sites per monomer, multiplied by the total amount of
specific protein [E]t) can be calculated from the above formula or by examination of the x axis intercept.
Binding parameters for EmrR in crude extract and isolated form were
very similar. In crude extracts of 1 mg of total protein/ml, with an estimated [E]t of 5.8 µM, the
n[E]t values were 18.6 µM for CCCP, 17.3 µM for FCCP, and 6.8 µM for DNP. These data do not take into account nonspecific binding, although for DNP, which shows essentially no nonspecific binding, they indicate one binding site per monomer. In
a 1-mg/ml solution of IMAC-purified protein (estimated
[E]t = 50 µM),
n[E]t = 43 µM for CCCP. This would
suggest approximately one binding site per monomer of EmrR. Similar
data were obtained for FCCP, n[E]t = 43 µM, and for DNP, n[E]t = 41 µM, i.e.,
one binding site per monomer. This comparison between the behavior of
EmrR in crude extract and in purified form suggests that the protein
does not require cofactor(s) for ligand binding.
Our data indicate that CCCP, FCCP, and DNP all bind to EmrR
specifically and with micromolar affinities. It appears that one ligand
binds per EmrR monomer. A homologous MarR repressor binds salicylate
and controls the expression of a global regulator, MarA, in E. coli (14-16, 19). The helix-turn-helix motif of the MarR family regulators is well defined and is located at the center of
the protein (2), suggesting that ligand binding is localized to the C- and/or N-terminal domain. We have expressed and purified the
C-terminal domain (amino acids 77 to 173) and found that it has no
ligand binding activity. The N-terminal domain (amino acids 1 to 88)
formed an insoluble protein, suggesting that work toward crystallization and understanding the mechanism of ligand binding will
have to be performed with the full-length dimeric protein. In
collaboration with G. Petsko's group, we recently obtained crystals of
EmrR (1a), and future structural work should reveal the
basis of drug recognition by this interesting multidrug sensor.
 |
ACKNOWLEDGMENTS |
We thank Victoria L. Haynes and Natalia Yakovleva for help with
some experiments.
This work was supported by NIH grant GM54412 and NSF grant MCB-9317013.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Biotechnology
Center, Tufts University, 4 Colby St., Medford, MA 02155. Phone: (617) 627-3731. Fax: (617) 627-3993. E-mail: klewis{at}tufts.edu.
 |
REFERENCES |
| 1.
|
Ahmed, M.,
C. M. Borsch,
S. S. Taylor,
N. Vazquez-Laslop, and A. A. Neyfakh.
1994.
A protein that activates expression of a multidrug efflux transporter upon binding the transporter substrates.
J. Biol. Chem.
269:28506-28513[Abstract/Free Full Text].
|
| 1a.
| Clifton, J., A. Brooun, K. Lewis, and G. Petsko.
Unpublished data.
|
| 2.
|
Dalrymple, B. P., and Y. Swadling.
1997.
Expression of a Butyrivibrio fibrisolvens E14 gene (cinB) encoding an enzyme with cinnamoyl ester hydrolase activity is negatively regulated by the product of an adjacent gene (cinR).
Microbiology
143:1203-1210[Abstract].
|
| 3.
|
del Castillo, I.,
J. E. Gonzalez-Pastor,
J. L. San Millan, and F. Moreno.
1991.
Nucleotide sequence of the Escherichia coli regulatory gene mprA and construction and characterization of mprA-deficient mutants.
J. Bacteriol.
173:3924-3929[Abstract/Free Full Text].
|
| 4.
|
Furukawa, H.,
J. T. Tsay,
S. Jackowski,
Y. Takamura, and C. O. Rock.
1993.
Thiolactomycin resistance in Escherichia coli is associated with the multidrug resistance efflux pump encoded by emrAB.
J. Bacteriol.
175:3723-3729[Abstract/Free Full Text].
|
| 5.
|
Grkovic, S.,
M. H. Brown,
N. J. Roberts,
I. T. Paulsen, and R. A. Skurray.
1998.
QacR is a repressor protein that regulates expression of the Staphylococcus aureus multidrug efflux pump QacA.
J. Biol. Chem.
273:18665-18673[Abstract/Free Full Text].
|
| 6.
|
Levy, S. B.
1998.
The challenge of antibiotic resistance.
Sci. Am.
278:46-53[Medline].
|
| 7.
|
Lewis, K.
1994.
Multidrug resistance pumps in bacteria: variations on a theme.
Trends Biochem. Sci.
19:119-123[Medline].
|
| 8.
|
Lewis, K.
1999.
Multidrug resistance: versatile drug sensors of bacterial cells.
Curr. Biol.
9:R403-R407[Medline].
|
| 9.
|
Lomovskaya, O.,
F. Kawai, and A. Matin.
1996.
Differential regulation of the mcb and emr operons of Escherichia coli: role of mcb in multidrug resistance.
Antimicrob. Agents Chemother.
40:1050-1052[Abstract].
|
| 10.
|
Lomovskaya, O., and K. Lewis.
1992.
Emr, an Escherichia coli locus for multidrug resistance.
Proc. Natl. Acad. Sci. USA
89:8938-8942[Abstract/Free Full Text].
|
| 11.
|
Lomovskaya, O.,
K. Lewis, and A. Matin.
1995.
EmrR is a negative upstream regulator of the E. coli multidrug resistance pump EmrAB.
J. Bacteriol.
177:2328-2334[Abstract/Free Full Text].
|
| 12.
|
Mao, W., and D. A. Siegele.
1998.
Genetic analysis of the stationary phase-induced mcb operon promoter in Escherichia coli.
Mol. Microbiol.
27:415-424[Medline].
|
| 13.
|
Markham, P. N.,
M. Ahmed, and A. A. Neyfakh.
1996.
The drug-binding activity of the multidrug-responding transcriptional regulator BmrR resides in its C-terminal domain.
J. Bacteriol.
178:1473-1475[Abstract/Free Full Text].
|
| 14.
|
Martin, R. G.,
K. W. Jair,
R. E. Wolf, Jr., and J. L. Rosner.
1996.
Autoactivation of the marRAB multiple antibiotic resistance operon by the MarA transcriptional activator in Escherichia coli.
J. Bacteriol.
178:2216-2223[Abstract/Free Full Text].
|
| 15.
|
Martin, R. G., and J. L. Rosner.
1995.
Binding of purified multiple antibiotic-resistance repressor protein (MarR) to mar operator sequences.
Proc. Natl. Acad. Sci. USA
92:5456-5460[Abstract/Free Full Text].
|
| 16.
|
Miller, P. F., and M. C. Sulavik.
1996.
Overlaps and parallels in the regulation of intrinsic multiple-antibiotic resistance in Escherichia coli.
Mol. Microbiol.
21:441-448[Medline].
|
| 17.
|
Nikaido, H.
1998.
Multiple antibiotic resistance and efflux.
Curr. Opin. Microbiol.
1:516-523.
[Medline] |
| 18.
|
Paulsen, I. T.,
M. H. Brown, and R. A. Skurray.
1996.
Proton-dependent multidrug efflux systems.
Microbiol. Rev.
60:575-608[Abstract/Free Full Text].
|
| 19.
|
Seoane, A. S., and S. B. Levy.
1995.
Characterization of MarR, the repressor of the multiple antibiotic resistance (mar) operon in Escherichia coli.
J. Bacteriol.
177:3414-3419[Abstract/Free Full Text].
|
| 20.
|
Zheleznova, E. A.,
P. N. Markham,
A. A. Neyfakh, and R. G. Brennan.
1999.
Structural basis of multidrug recognition by BmrR, a transcription activator of a multidrug transporter.
Cell
96:353-362[Medline].
|
Journal of Bacteriology, August 1999, p. 5131-5133, Vol. 181, No. 16
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.